329 related articles for article (PubMed ID: 35233693)
1. Switching from aflibercept to brolucizumab for the treatment of refractory neovascular age-related macular degeneration.
Ota H; Takeuchi J; Nakano Y; Horiguchi E; Taki Y; Ito Y; Terasaki H; Nishiguchi KM; Kataoka K
Jpn J Ophthalmol; 2022 May; 66(3):278-284. PubMed ID: 35233693
[TBL] [Abstract][Full Text] [Related]
2. Short-term outcomes of switching to brolucizumab in japanese patients with neovascular age-related macular degeneration.
Kitajima Y; Maruyama-Inoue M; Ikeda S; Ito A; Inoue T; Yanagi Y; Kadonosono K
Jpn J Ophthalmol; 2022 Nov; 66(6):511-517. PubMed ID: 36149566
[TBL] [Abstract][Full Text] [Related]
3. MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid.
Khanani AM; Brown DM; Jaffe GJ; Wykoff CC; Adiguzel E; Wong R; Meng X; Heier JS;
Ophthalmology; 2022 Sep; 129(9):974-985. PubMed ID: 35537533
[TBL] [Abstract][Full Text] [Related]
4. One-year results of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization.
Matsumoto H; Hoshino J; Mukai R; Nakamura K; Akiyama H
Sci Rep; 2022 May; 12(1):8195. PubMed ID: 35581196
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal Aflibercept versus Brolucizumab for Treatment-Naive Neovascular Age-Related Macular Degeneration with Type 1 Macular Neovascularization: Comparison of Short-Term Outcomes.
Hoshino J; Matsumoto H; Mukai R; Nakamura K; Akiyama H
Ophthalmologica; 2022; 245(5):413-420. PubMed ID: 35834995
[TBL] [Abstract][Full Text] [Related]
6. Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial.
Dugel PU; Jaffe GJ; Sallstig P; Warburton J; Weichselberger A; Wieland M; Singerman L
Ophthalmology; 2017 Sep; 124(9):1296-1304. PubMed ID: 28551167
[TBL] [Abstract][Full Text] [Related]
7. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
Dugel PU; Koh A; Ogura Y; Jaffe GJ; Schmidt-Erfurth U; Brown DM; Gomes AV; Warburton J; Weichselberger A; Holz FG;
Ophthalmology; 2020 Jan; 127(1):72-84. PubMed ID: 30986442
[TBL] [Abstract][Full Text] [Related]
8. Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration.
Kataoka K; Itagaki K; Hashiya N; Wakugawa S; Tanaka K; Nakayama M; Yamamoto A; Mukai R; Honjyo J; Maruko I; Kawai M; Miyara Y; Terao N; Wakatsuki Y; Onoe H; Mori R; Koizumi H; Sekiryu T; Iida T; Okada AA;
Graefes Arch Clin Exp Ophthalmol; 2024 Jan; 262(1):43-51. PubMed ID: 37668741
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of brolucizumab in age-related macular degeneration: A systematic review of real-world studies.
Baumal CR; Sørensen TL; Karcher H; Freitas RL; Becher A; Balez S; Clemens A; Singer M; Kodjikian L
Acta Ophthalmol; 2023 Mar; 101(2):123-139. PubMed ID: 36117281
[TBL] [Abstract][Full Text] [Related]
10. Brolucizumab for recalcitrant macular neovascularization in age-related macular degeneration with pigment epithelial detachment.
Chronopoulos A; Huynh E; Ashurov A; Schutz JS; Jonas JB; Hattenbach LO
Eur J Ophthalmol; 2024 Mar; 34(2):487-496. PubMed ID: 37461836
[TBL] [Abstract][Full Text] [Related]
11. HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
Dugel PU; Singh RP; Koh A; Ogura Y; Weissgerber G; Gedif K; Jaffe GJ; Tadayoni R; Schmidt-Erfurth U; Holz FG
Ophthalmology; 2021 Jan; 128(1):89-99. PubMed ID: 32574761
[TBL] [Abstract][Full Text] [Related]
12. Comparison of functional and morphologic changes between brolucizumab and faricimab in neovascular age-related macular degeneration.
Maruyama-Inoue M; Yanagi Y; Inoue T; Kadonosono K
Graefes Arch Clin Exp Ophthalmol; 2024 Feb; 262(2):589-599. PubMed ID: 37750953
[TBL] [Abstract][Full Text] [Related]
13. Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER.
Monés J; Srivastava SK; Jaffe GJ; Tadayoni R; Albini TA; Kaiser PK; Holz FG; Korobelnik JF; Kim IK; Pruente C; Murray TG; Heier JS
Ophthalmology; 2021 Jul; 128(7):1050-1059. PubMed ID: 33207259
[TBL] [Abstract][Full Text] [Related]
14. Two-year outcomes of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization.
Matsumoto H; Hoshino J; Nakamura K; Akiyama H
Sci Rep; 2023 Feb; 13(1):3249. PubMed ID: 36828853
[TBL] [Abstract][Full Text] [Related]
15. Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors.
Ho VY; Yeh S; Olsen TW; Bergstrom CS; Yan J; Cribbs BE; Hubbard GB
Am J Ophthalmol; 2013 Jul; 156(1):23-28.e2. PubMed ID: 23664153
[TBL] [Abstract][Full Text] [Related]
16. Two-Year Outcomes of Treat-and-Extend Intravitreal Aflibercept for Exudative Age-Related Macular Degeneration: A Prospective Study.
Maruko I; Ogasawara M; Yamamoto A; Itagaki K; Hasegawa T; Arakawa H; Nakayama M; Koizumi H; Okada AA; Sekiryu T; Iida T
Ophthalmol Retina; 2020 Aug; 4(8):767-776. PubMed ID: 32417356
[TBL] [Abstract][Full Text] [Related]
17. Two-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocol.
Jørstad ØK; Faber RT; Moe MC
Acta Ophthalmol; 2017 Aug; 95(5):460-463. PubMed ID: 28556485
[TBL] [Abstract][Full Text] [Related]
18. Comparative assessment of subretinal hyper-reflective material in patients treated with brolucizumab versus aflibercept in HAWK and HARRIER.
Sadda S; Sarraf D; Khanani AM; Tadayoni R; Chang AA; Saffar I; Gedif K; Wong DT
Br J Ophthalmol; 2024 May; 108(6):852-858. PubMed ID: 37669850
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies.
Lally DR; Loewenstein A; Arnold JJ; Yang YC; Gedif K; Best C; Patel H; Tadayoni R; Heier JS
Eye (Lond); 2023 Apr; 37(6):1242-1248. PubMed ID: 35597816
[TBL] [Abstract][Full Text] [Related]
20. Short-term outcomes of intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy.
Matsumoto H; Hoshino J; Mukai R; Nakamura K; Akiyama H
Sci Rep; 2021 Mar; 11(1):6759. PubMed ID: 33762600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
